news
DiversityInc names Lilly a top company for diversity
25 April 2012 | By Eli Lilly and Company
Eli Lilly and Company has been named to the 2012 DiversityInc Top 50 Companies for Diversity list...
List view / Grid view
Eli Lilly & Company
news
FDA approves Amyvid™
6 April 2012 | By Eli Lilly and Company
Amyvid is the first and only radioactive diagnostic agent approved for PET imaging of beta-amyloid neuritic plaques in the living brain...
news
Lilly targets faulty c-MET receptor in cancer research studies presented at AACR Meeting
2 April 2012 | By Eli Lilly and Company
Studies provided basis for ongoing Phase I, II studies in gastric, other cancers...
news
BYETTA® approved for use with basal insulin in Europe
23 March 2012 | By Amylin Pharmaceuticals, Inc.
Patients in pivotal study achieved better glycemic control overall and after meals...
news
Jentadueto™ tablets, now available in U.S. pharmacies
7 March 2012 | By Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Jentadueto™ (linagliptin/metformin hydrochloride) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S.
news
Lilly introduces global ‘Innovation Starts Here’ initiative to foster innovation and quality science
28 February 2012 | By Eli Lilly and Company
Lilly award programs also further research and development investment in Europe...
news
CHMP recommends approval of BYETTA® for use with basal insulin
17 February 2012 | By Eli Lilly and Company
Patients in pivotal study achieved better glycemic control without weight gain...
news
FDA approves Jentadueto™ (linagliptin/metformin hydrochloride) tablets for the treatment of adult patients with type 2 diabetes
30 January 2012 | By Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto™ (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin. JENTADUETO provides a new, single-tablet treatment option, taken twice-daily, for patients who…
news
Elanco Animal Health announces Lilly’s agreement to acquire ChemGen Corp.
24 January 2012 | By Eli Lilly and Company
Elanco, announced that Lilly has signed an agreement to acquire ChemGen Corp., a privately held bioscience company...
news
Katherine Baicker elected to Lilly Board of Directors
12 December 2011 | By Eli Lilly and Company
Board of Directors of Eli Lilly and Company has elected Katherine Baicker, Ph.D. as a new member, effective December 12, 2011...
news
Lilly oncology reveals findings from study of JAK2 inhibitor for blood cancers at ASH meeting
12 December 2011 | By Eli Lilly and Company
Data from an oncology pipeline molecule announced at the ASH meeting...
news
Lilly provides additional funding to Infectious Disease Research Institute to identify new Tuberculosis therapies
17 November 2011 | By Eli Lilly and Company
Eli Lilly and Company is providing more than $4 million in additional funding...
news
Data shows effects of Effient in STEMI patients
16 November 2011 | By Eli Lilly and Company
An analysis of the TRITON-TIMI 38 trial presented...
news
Lilly CEO Lechleiter outlines opportunities for improved health and economic growth in Asia-Pacific region
10 November 2011 | By Eli Lilly and Company
New trade agreements, effective public policies, and continued collaboration...
news
FDA approves ERBITUX® (cetuximab) for first-line Recurrent Locoregional or Metastatic Head and Neck Cancer in Combination with Platinum-based Chemotherapy with 5-Fluorouracil
7 November 2011 | By Bristol-Myers Squibb Company
ERBITUX now approved for five indications across two tumor types...
